ABO blood groups and deep vein thrombosis;Système de groupe sanguin ABO et thrombose veineuse profonde

Sang Thrombose Vaisseaux

Volumn 16, Issue 2, 2004, Pages 96-100

  Robert, Annie ^a   Eschwège, Valérie ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

ABO blood groups; Deep vein thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; ORAL CONTRACEPTIVE AGENT; VON WILLEBRAND FACTOR;

BLOOD GROUP A; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP O; BLOOD GROUP TYPING; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; EVALUATION; GENDER; GENE MUTATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; RISK ASSESSMENT; RISK FACTOR; SHORT SURVEY; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 1842480383     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. Jick H, Westerholm B, Vessey MP, et al. Venous thromboembolic disease and ABO blood group type. A cooperative study. Lancet 1969; 1: 539-42.
2. Talbot S, Ryrie D, Wakley EJ, Langman MJS. ABO blood-group and venous thromboembolic disease. Lancet 1970; 1: 1257-9.
3. Jick H, Porter J. Thrombophlebitis of the lower extremities and ABO blood type. Arch Intern Med 1978; 138: 1566-7.
4. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
5. Wautrecht JC, Galle C, Motte S, Dereume JP, Dramaix M. The role of ABO blood groups in the incidence of deep vein thrombosis. Thromb Haemost 1998; 79: 689-90.
6. Gonzáles Ordóñez AJ, Medina Rodriguez JM, Martin L, Alvarez V, Coto E. The O blood group protects against venous thromboembolism in individuals with the factor V Leiden but not the prothrombin (factor II G20210A) mutation. Blood Coagul Fibrinolysis 1999; 10: 303-7.
7. Westerholm B, Wiechel B, Eklund G. Oral contraceptives, venous thromboembolic disease, and ABO blood type. Lancet 1971; 2: 664.
8. Koster T, Blann AD, Briët E, Vandenbroocke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurence of deep-vein thrombosis. Lancet 1995; 345: 152-4.
9. Robert A, Aillaud MF, Eschwège V, Randrianjohany A, Scarabin Y, Juhan-Vague I. ABO blood group and risk of venous thrombosis in heterozygous carriers of factor V Leiden. Thromb Haemost 2000; 83: 630-1.
10. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-730.
11. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population. Evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985; 37: 89-101.
12. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987; 69: 1691-5.
13. Souto JC, Almasy L, Muniz-Diaz E, et al. J. Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 2000; 20: 2024-8.
14. Kraaijenhagen RA, in't Anker PS, Koopman MM, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
15. Kamphuisen PW, Eikenboom JCJ, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-8.
16. Kaufman RJ, Pipe SW. Regulation of factor VIII expression and activity by von Willebrand factor. Thromb Haemost 1999; 82: 201-8.
17. Souto JC, Almasy L, Soria JM, et al. Genome wide-linkage analysis of von Willebrand factor plasma levels: results from GAIT project. Thromb Haemost 2003; 89: 468-74.
18. Sodetz JM, Paulson JC, McKee PA. Carbohydrate composition and identification of blood group A, B and H oligosaccharide structures on human factor VIII/von Willebrand factor. J Biol Chem 1979; 254: 10754-60.
19. Matsui T, Titani K, Mizuochi T. Structures of the asparagine-linked oligosaccharide chains of human von Willebrand factor. Occurrence of blood group A, B and H(O)structures. J Biol Chem 1992; 267: 8723-31.
20. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Amount of H antigen expressed on circulating von Willebrand factor is modified by ABO blood group genotype and is a major determinant of plasma von Willebrand factor antigen levels. Arterioscler Thromb Vasc Biol 2002; 22: 335-41.
21. Federici AB, Elder JH, De Marco L, Ruggeri ZM, Zimmerman TS. Carbohydrate moiety of von Willebrand factor is not necessary for maintaining multimeric structure and ristocetin cofactor activity but protects from proteolytic degradation. J Clin Invest 1984; 74: 2049-55.
22. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. J Thromb Haemost 2003; 1: 33-40.